Japanese NDA Submitted for Imeglimin; Poxel H1 ’20 Earnings Update
Yesterday, Poxel hosted its H1 ’20 earnings call and provided updates to its Japanese and US Imeglimin development. Of note, Poxel has submitted the Japanese NDA for Imeglimin and its US partner, Metavant, is actively preparing to initiate a Ph3 program in the US. Below, FENIX provides an overview of the Poxel earnings call and thoughts on Imeglimin development, including its market potential.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.